Modified antibodies
AssigneeJanux Therapeutics, Inc.
InventorsDavid Campbell, Ramesh Bhatt, William J. Dower, Steven E. Cwirla, Blake M. Williams
Life of this patent
Estimating the term…
Abstract
Provided herein are modified antibodies, pharmaceutical compositions thereof, as well as nucleic acids, and methods for making and discovering the same. The modified antibodies described herein are modified with a peptide. The peptide binds at or near the antigen binding site of the antibody at physiological pH, thus reducing binding affinity of the antibody for a target antigen. At acidic pH, the binding interaction of the peptide at or near the antigen binding site is disrupted, thus enabling binding with a target antigen.
Claims19
A method for preparing a modified antibody that has reduced binding affinity for a target antigen at physiological pH relative to its binding affinity for the target antigen at acidic pH, the method comprising:
- 1) screening a library of peptide sequences to identify a peptide sequence that has higher binding affinity for an antibody in an unmodified form at physiological pH relative to its binding affinity for the antibody in unmodified form at acidic pH;
- wherein the library of peptide sequences comprises one or more peptide sequences with at least one cysteine residue, followed by 2) linking the identified peptide sequence to the antibody with a linking moiety to provide the modified antibody, wherein the modified antibody comprises the formula A-L-P, wherein A is the antibody, L is the linking moiety and P is the identified peptide sequence.
Dependencies are inferred from the claim text.